Par Drugs & Che.

Which are the latest news on Par Drugs & Che.?

Why is Par Drugs & Chemicals Ltd falling/rising?

As of 05-Sep, Par Drugs & Chemicals Ltd's stock price is 156.71, down 5.0%, despite a strong 1-year return of 57.48%. The decline is linked to recent underperformance and high valuation concerns, but the company remains net-debt free with impressive financial growth.

As of 05-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 156.71, which reflects a change of -8.24 (-5.0%). Despite this drop, the stock has shown strong performance over various periods, with a 1-year return of 57.48%, significantly outperforming the market benchmark (BSE500) which returned only 1.51% in the same timeframe.<BR><BR>The stock's recent decline can be attributed to its underperformance today, where it lagged behind its sector by 5.27%. Additionally, while the stock is trading above its moving averages across multiple timeframes, the immediate market reaction has led to a decrease in price. <BR><BR>However, it is important to note that the company remains net-debt free and has reported impressive growth in its financial metrics, including a 62.2% increase in profit before tax and a 43.7% increase in profit after tax compared to the previous four-quarter average. The highest net sales recorded at Rs 31.28 crore also indicate strong operational performance.<BR><BR>Despite the current price drop, the stock's overall trajectory has been positive over the past year, and it continues to attract investor interest, as evidenced by a significant rise in delivery volume. Nonetheless, the stock's premium valuation compared to peers and a high PEG ratio of 5.7 may contribute to investor caution, impacting its price movement in the short term.

Who are in the management team of Par Drugs & Che.?

The management team of Par Drugs & Che includes Falgun Vallabhbhai Savani (Chairman & Managing Director), Jigneshbhai Vallabhbhai Savani (Executive Director & CEO), and several other directors, both executive and independent, who oversee the company's operations and strategy.

The management team of Par Drugs & Che includes the following key individuals:<BR><BR>1. **Falgun Vallabhbhai Savani** - Chairman & Managing Director<BR>2. **Jigneshbhai Vallabhbhai Savani** - Executive Director & CEO<BR>3. **Ghanshayambhai Bhagvanbhai Savani** - Whole-Time Director & Executive Director<BR>4. **Nayna Jignesh Savani** - Non-Executive Director<BR>5. **Krishna Mitulbhai Shah** - Independent Non-Executive Director<BR>6. **Kajal Chintanbhai Vaghani** - Independent Non-Executive Director<BR>7. **Pravin Manjibhai Bhayani** - Independent Non-Executive Director<BR>8. **Bintal Bhaveshkumar Shah** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Par Drugs & Che. do?

Par Drugs and Chemicals Ltd is a Micro Cap company in the Chemicals & Petrochemicals industry, reporting net sales of 31 Cr and a net profit of 5 Cr for June 2026. It has a market cap of INR 125 Cr, a P/E ratio of 10.00, and a return on equity of 12.94%.

Overview:<BR>Par Drugs and Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited Company in 1999 and later converted into a Public Limited Company in 2018. The latest quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 31 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 5 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 125 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 10.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.37 <BR>Return on Equity: 12.94% <BR>Price to Book: 1.10 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Par Drugs & Che.?

Par Drugs & Che. peers include Indian Phosphate, Arvee Laborat., Jocil, and others, with average management risk and growth. Its 1-year return is 18.86%, higher than Indian Emuls but lower than Indian Phosphate's 36.67%.

Peers: The peers of Par Drugs & Che. are Indian Phosphate, Arvee Laborat., Jocil, Vital Chemtech, Hindcon Chemical, Paragon Fine, Indian Emuls, Unilex Colour &C, Vadivarhe Speci., and Nilachal Carbo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Paragon Fine and Indian Phosphate, while Average management risk is found at Par Drugs & Che., Jocil, Hindcon Chemical, and Indian Emuls, and the rest. Below Average management risk is noted at Arvee Laborat., Vital Chemtech, Unilex Colour &C, Vadivarhe Speci., and Nilachal Carbo. Growth is Excellent at Indian Emuls, while Average growth is seen at Par Drugs & Che., Jocil, and the rest, and Below Average growth is present at Indian Phosphate, Arvee Laborat., Vital Chemtech, Hindcon Chemical, Paragon Fine, Unilex Colour &C, Vadivarhe Speci., and Nilachal Carbo. Capital Structure is Excellent at Par Drugs & Che., Indian Phosphate, and Paragon Fine, Good at Arvee Laborat. and Hindcon Chemical, and Below Average at Vital Chemtech, Indian Emuls, Unilex Colour &C, Vadivarhe Speci., and Nilachal Carbo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indian Phosphate at 36.67%, while the peer with the lowest is Indian Emuls at -70.55%. Par Drugs & Che. has a 1-year return of 18.86%, which is significantly higher than Indian Emuls but lower than Indian Phosphate. Additionally, Hindcon Chemical, Indian Emuls, Unilex Colour &C, and Vadivarhe Speci. have negative six-month returns.

How big is Par Drugs & Che.?

As of 31st August, Par Drugs & Chemicals Ltd has a market capitalization of 125.00 Cr, with recent Net Sales of 108.89 Cr and a Net Profit of 14.49 Cr. Shareholder's Funds are 98.97 Cr and Total Assets are 119.39 Cr as of March 2025.

As of 31st August, Par Drugs & Chemicals Ltd has a market capitalization of 125.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 108.89 Cr and a Net Profit of 14.49 Cr.<BR><BR>For the latest annual period ending in March 2025, Shareholder's Funds amounted to 98.97 Cr, while Total Assets were reported at 119.39 Cr.

Should I buy, sell or hold Par Drugs & Chemicals Ltd?

Are Par Drugs & Chemicals Ltd latest results good or bad?

Par Drugs & Chemicals Ltd's latest results are concerning, with net sales dropping 33.16% to ₹19.61 crores and net profit falling 82.29% to ₹0.85 crores, indicating significant operational challenges and a decline in profitability. Investors should be cautious given these negative trends.

The latest results for Par Drugs & Chemicals Ltd indicate a significant downturn in performance, marking a challenging quarter for the company. In the March 2026 quarter, net sales dropped by 33.16% sequentially to ₹19.61 crores, which is the lowest quarterly sales figure in recent times. Additionally, net profit plummeted by 82.29% to just ₹0.85 crores, reflecting a sharp decline in profitability.<BR><BR>Operating margins also suffered, collapsing to 7.34% from 20.65% in the previous quarter, highlighting severe operational challenges. This deterioration stands in stark contrast to the company's strong nine-month performance, where net profit had surged by 153.36% earlier in the fiscal year.<BR><BR>Overall, the results are concerning, with multiple indicators pointing to operational difficulties and a decline in both revenue and profitability. Investors should be cautious as these trends raise questions about the company's ability to sustain its previous performance levels.

Is Par Drugs & Che. overvalued or undervalued?

As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. <BR><BR>In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present.

How has been the historical performance of Par Drugs & Che.?

Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.

Answer:<BR>The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantly to 119.39 Cr in Mar'25 from 60.12 Cr in Mar'20, with total liabilities also increasing to 119.39 Cr in Mar'25. Cash flow from operating activities was 16.00 Cr in Mar'25, although the net cash outflow was -9.00 Cr, down from a net inflow of 14.00 Cr in Mar'24. Overall, Par Drugs & Che. has shown robust growth in sales and profitability, despite some challenges in cash flow management.

What is the technical trend for Par Drugs & Che.?

As of May 12, 2025, Par Drugs & Che exhibits a mildly bearish trend overall, with mixed signals from key indicators such as a mildly bullish weekly MACD and bearish daily moving averages.

As of 12 May 2025, the technical trend for Par Drugs & Che has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory shows a mildly bullish trend on the weekly chart with no trend on the monthly. The OBV is mildly bearish weekly and mildly bullish monthly. Overall, the current stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands contributing to this view.

Who are the top shareholders of the Par Drugs & Che.?

The top shareholder of Par Drugs & Che. is Jignesh Vallabhbhai Savani, holding 21.88%. Other significant shareholders include Econo Trading And Investment Private Limited at 1.78% and individual investors with a combined stake of 20.3%.

The top shareholders of Par Drugs & Che. include the promoters, with Jignesh Vallabhbhai Savani holding the highest stake at 21.88%. There are no pledged promoter holdings, and the company is also held by two foreign institutional investors, although their combined stake is negligible at 0.0%. The highest public shareholder is Econo Trading And Investment Private Limited, which holds 1.78%. Additionally, individual investors collectively hold 20.3% of the company.

When is the next results date for Par Drugs & Che.?

No Upcoming Board Meetings

What is the bonus history of the Par Drugs & Che.?

Par Drugs & Chemicals Ltd issued a 1:1 bonus on April 27, 2021, with a record date of April 28, 2021, granting shareholders an additional share for each share held.

Par Drugs & Chemicals Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of April 27, 2021. The record date for this bonus was April 28, 2021. This means that shareholders on record as of that date received an additional share for every share they held.

Has Par Drugs & Che. declared dividend?

Par Drugs & Chemicals Ltd has declared a 12% dividend, amounting to 1.2 per share, with an ex-date of November 22, 2021. Despite the dividend declaration, the dividend yield is 0%, and the company has experienced significant volatility in total returns, ranging from -57.37% over 6 months to 495.27% over 5 years.

Par Drugs & Chemicals Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 22 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -57.37%, the dividend return was 0%, resulting in a total return of -57.37%.<BR><BR>In the 1-year period, the price return was -55.99%, the dividend return was 0%, resulting in a total return of -55.99%.<BR><BR>In the 2-year period, the price return was -52.72%, the dividend return was 0%, resulting in a total return of -52.72%.<BR><BR>In the 3-year period, the price return was -32.61%, the dividend return was 0%, resulting in a total return of -32.61%.<BR><BR>In the 4-year period, the price return was 51.47%, the dividend return was 1.31%, resulting in a total return of 52.78%.<BR><BR>In the 5-year period, the price return was 490.29%, the dividend return was 4.98%, resulting in a total return of 495.27%.<BR><BR>Overall, while Par Drugs & Chemicals Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show significant volatility, with negative returns in the shorter terms and substantial positive returns over the longer term, particularly in the 5-year period.